PRSA news

Latest 1 stories · newest Nov 5, 2026

PRSA

Processa completes $200 million acquisition of Vidya Therapeutics

Processa acquired Vidya Therapeutics and raised $200 million to advance its immunological and inflammatory disease pipeline, including VT-7208 into Phase 2 for conditions like food allergy.

M&A Nov 5, 2026 sentiment +0.30 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same PRSA feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/PRSA/newsSTART FREE